Serious Games for Serious Outcomes: Enhancing Cognition, Balance, and Quality of Life in Children With Cerebral Palsy
Launched by NATALIYA HRABARCHUK ·
Trial Information
Current as of September 25, 2025
Recruiting
Keywords
ClinConnect Summary
This study is testing whether serious games from the Vana Vital platform, used during daily sessions, can help children with cerebral palsy improve balance, trunk control, thinking skills, and overall quality of life when added to usual rehab. The games are designed to make kids move and think at the same time (dual-tasking). The trial randomly assigns children to one of three groups: (1) standard rehab plus 30 minutes of serious games daily for 10 days, (2) standard rehab plus an extra 30 minutes of physical therapy, or (3) standard rehab alone. The main thing researchers measure is trunk control using the Trunk Control Measurement Scale (TCMS) at the start and after about two weeks; they’ll also assess balance, cognition, and quality of life.
Eligible participants are children aged 6 to 14 with cerebral palsy who can attend school and have GMFCS levels I–III (meaning they can walk with or without help). Exclusions include GMFCS levels IV–V, uncooperative behavior, or uncontrolled seizures. The study is taking place at Elita Rehabilitation Center in Lviv, Ukraine, and plans to enroll about 30 children. It is currently recruiting, with completion expected around January 2026. Results will be shared in aggregated form (no individual data publicly), and evaluators are kept unaware of which group each child is in to ensure fair assessment.
Gender
ALL
Eligibility criteria
About Nataliya Hrabarchuk
Nataliya Hrabarchuk is a dedicated clinical trial sponsor focused on advancing high-quality, ethically conducted research. She provides strategic oversight of study design, regulatory compliance, safety monitoring, and data integrity while coordinating effectively with investigators, contract research organizations, and regulatory authorities. Committed to patient welfare and Good Clinical Practice standards, she emphasizes robust study governance, transparent communication, and timely delivery of reliable clinical evidence to support therapeutic development.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported